In contrast, no significant between-country differences in median CD4 cell count at week 24 (p = 0.82), week 48 (p = 0.19), or percent change in CD4 cell count from baseline by week 24 or 48 of cART was observed among TB-HIV patients co-treated with rifampicin based anti-tuberculosis. The gene discussed is CD4; the disease is tuberculosis.